-$0.02 Earnings Per Share Expected for Antares Pharma Inc (ATRS) This Quarter

Analysts expect Antares Pharma Inc (NASDAQ:ATRS) to announce earnings of ($0.02) per share for the current quarter, Zacks reports. Five analysts have provided estimates for Antares Pharma’s earnings, with the lowest EPS estimate coming in at ($0.03) and the highest estimate coming in at ($0.01). Antares Pharma posted earnings of ($0.03) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 33.3%. The business is scheduled to report its next earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.13) to ($0.07). For the next financial year, analysts forecast that the firm will report earnings of $0.07 per share, with EPS estimates ranging from $0.00 to $0.18. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. The firm had revenue of $14.16 million for the quarter, compared to analyst estimates of $13.70 million.

ATRS has been the topic of several research analyst reports. BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. ValuEngine raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Finally, HC Wainwright set a $4.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 8th.

In related news, Director Jacques Gonella sold 49,507 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $3.09, for a total value of $152,976.63. Following the sale, the director now directly owns 9,985,848 shares of the company’s stock, valued at $30,856,270.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Robert F. Apple sold 43,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $3.75, for a total transaction of $161,250.00. Following the completion of the transaction, the chief executive officer now owns 1,573,562 shares in the company, valued at approximately $5,900,857.50. The disclosure for this sale can be found here. Insiders sold 343,000 shares of company stock worth $1,088,250 over the last three months. Corporate insiders own 12.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new position in Antares Pharma in the first quarter valued at approximately $1,959,000. JPMorgan Chase & Co. raised its holdings in Antares Pharma by 533.6% in the first quarter. JPMorgan Chase & Co. now owns 448,634 shares of the specialty pharmaceutical company’s stock valued at $987,000 after buying an additional 377,824 shares during the period. United Services Automobile Association raised its holdings in Antares Pharma by 1,453.0% in the second quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after buying an additional 379,166 shares during the period. Mycio Wealth Partners LLC purchased a new position in Antares Pharma in the second quarter valued at approximately $6,278,000. Finally, Wells Fargo & Company MN raised its holdings in Antares Pharma by 21.5% in the first quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock valued at $4,253,000 after buying an additional 342,062 shares during the period. Hedge funds and other institutional investors own 38.93% of the company’s stock.

Shares of ATRS traded up $0.04 during mid-day trading on Friday, hitting $3.21. The company had a trading volume of 706,357 shares, compared to its average volume of 1,527,002. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.89 and a current ratio of 2.33. Antares Pharma has a 1-year low of $1.58 and a 1-year high of $4.09. The stock has a market capitalization of $516.39 million, a PE ratio of -29.18 and a beta of 0.34.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Google Finance Portfolio

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply